The unequivocal changes in the three metric measures generally used to assess the predictive ability of a marker (AUC, IDI, NRI) all underline that combining biological (ATTR biomarker staging) and functional markers (pVO2 and FVC) synergistically improved prognostic resolution in our cohort of patients with transthyretin cardiac amyloidosis. Here, TTR is linked to cardiac amyloidosis.